The Global Pharmacogenomics Market was valued at US$ 5.58 Billion in 2024 and is expected to grow at a CAGR of 10.6% from 2024 to 2034. In 2024, North America led the market, achieving over 48.5% share with a revenue of US$ 2.7 Billion.
The Pharmacogenomics Market is scaling rapidly in 2025 as primary care practices adopt population-level drug-gene testing. Health systems offer panel-based genotyping during annual wellness visits, creating a lifetime record used for future prescriptions. When patients require new medications, providers consult stored pharmacogenomic data—eliminating delays from reactive testing. Population initiatives have enrolled over 100,000 patients in multiple health networks, with data integrated into medication decision tools. Early outcomes show a 40% drop in emergency visits related to drug reactions.
These systems prioritize high-impact genes such as CYP2C9, VKORC1, and SLCO1B1, ensuring precision dosing for warfarin, statins, and NSAIDs. As genotyping costs decline, population-based pharmacogenomics is becoming a cornerstone of preventive medication safety—redefining prescription protocols in primary care.
Click here for more information:
https://market.us/report/pharmacogenomics-market/Key Takeaways
The Pharmacogenomics market generated a revenue of US$ 5.6 Billion and is predicted to reach US$ 15.3 Billion, with a CAGR of 10.6%.
Based on the Technology, the Polymerase Chain Reaction segment generated the most revenue for the market with a market share of 45.9%.
Based on the application, the Oncology segment generated the most revenue for the market with a market share of 35.2%.
Based on the End-User, the Hospital & Clinics segment generated the most revenue for the market with a market share of 48.7%.
Region-wise, North America remained the lead contributor to the market, by claiming the highest market share, amounting to 48.5%.
Key Market Segments
By Technology
Sequencing
Microarray
Polymerase Chain Reaction
Others
By Application
Drug Discovery
Infectious Diseases
Oncology
Cardiovascular Diseases
Other Applications
By End-User
Hospital & Clinics
Research Organizations
Others
Emerging Trends
Preemptive genotyping panels rolled out during wellness exams.
Embedded drug-gene alerts for commonly prescribed medications.
Health systems target high-risk genes like CYP2C9, VKORC1, SLCO1B1.
Population-scale pharmacogenomic initiatives reducing adverse drug events.
Use Cases
A patient’s VKORC1 genotype guides warfarin dosing at therapy start.
Stored SLCO1B1 results alert provider to use low-dose simvastatin.
Automated alerts prevent prescribing NSAIDs to high-risk patients.
Health initiatives report fewer pharmacogenomic-related hospital visits.
Locked
